Raymond James Financial’s Cocrystal Pharma COCP Stock Holding History

Raymond James Financial’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-215	Closed	-$321	–	5320
2025 Q2	$321	Buy	+215	New	+$320	﹤0.01%	6732

Other funds holding COCP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Raymond James Financial's COCP Position: Q3 2025 in Review

Raymond James Financial sold out of Cocrystal Pharma (COCP) in Q3 2025, closing a stake of 215 shares — an estimated $321 sold.

Raymond James Financial first reported a position in COCP in Q2 2025 and held it in 1 quarter. The position peaked at $321 in Q2 2025. 22 funds tracked by Wall St. Rank hold COCP as of Q3 2025.

Raymond James Financial reported no remaining Cocrystal Pharma position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 215 Cocrystal Pharma shares in Q3 2025, an estimated $321.
Raymond James Financial first reported a position in Cocrystal Pharma in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Cocrystal Pharma position peaked at $321 in Q2 2025.
22 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.